BioPharm International, June 2006 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International, June 2006
Featured Article
Producing Proteins Using Transgenic Oilbody-Oleosin Technology
By Nancy Markley , Cory Nykiforuk, Ph.D. , Joe Boothe, Ph.D. , Maurice Moloney, Ph.D.
Transgenics can substantially reduce capital investment and lower production costs through economies of scale and more flexible scale-up.
Articles
Filter Integrity Testing in the Pharmaceutical Process Environment
By Reinhard Baumfalk , Jerry Finazzo
Air filtration also needs a filter integrity test method to guarantee the sterility of critical parameters.
The Case for Disposable Manufacturing Equipment toAccelerateVaccine
By Hélène Pora
Disposables can be used for media preparation, clarification, filling in downstream processes . . .
Pursuing Pharmaceutical Quality and Economy
By Bikash Chatterjee
Motorola recognized that vartion is the death knell of any process, so the company established a methodology called Six Sigma
Columns and Departments
Regulatory Beat: FDA's Field Force Does More With Less
By Jill Wechsler
Glavin is preparing a plan to modernize ORA through organizational changes . . .
StreetTalk: Enter the Dragon: China Biopharm Market is a Land
By Brian O'Connell
The top 10 Chinese companies in the biopharm sector account for only 20% of the market... leaving plenty of room for growth for Western companies.
Operations Excellence: Perfecting IT Management SystemSelectionforBiopharmaceutical Organizations
By Marc Puich
The overhead expense that comes along with each new enterprise application adds up quickly, and can be somewhat invisible to owners of the system.
Final Word: The US is Falling Behind on Generic Biopharmaceuticals
By Charles E. DiLiberti
Without generic competition, the US is at risk of losing its position of leadership in biopharmaceuticals.
From the Editor in Chief: When Does Glycosylation Matter?
By Laura Bush
The belief that glycosylation is critical to ensuring the functionality of protein therapeutics—and preventing immunogenicity—drives many manufacturing decisions. But is it time to question this industry tenet?

ADVERTISEMENT

ADVERTISEMENT

Click here